

Gary D Novack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7036998/publications.pdf>

Version: 2024-02-01

274
papers

5,463
citations

81743

39
h-index

91712

69
g-index

280
all docs

280
docs citations

280
times ranked

3417
citing authors

#	ARTICLE	IF	CITATIONS
1	Calculating efficacy of new ophthalmic treatments. The new calculus. <i>Ocular Surface</i> , 2022, 23, 219-223.	2.2	0
2	Schlenker et al.: How mean intraocular pressures are failing patients (<i>Ophthalmology Glaucoma</i> .) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.9	0
3	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, , .	0.6	0
4	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, 38, 201-202.	0.6	0
5	Expedited regulatory product approval in the time of COVID-19. <i>Ocular Surface</i> , 2022, , .	2.2	0
6	Off-Label Use as a Standard of Care. <i>American Journal of Ophthalmology</i> , 2021, 224, A6-A8.	1.7	2
7	Repurposing medications. <i>Ocular Surface</i> , 2021, 19, 336-340.	2.2	18
8	What is an adequate and well controlled study?. <i>Ocular Surface</i> , 2021, 20, 215-218.	2.2	2
9	Eyes on New Product Development: Regulations, Generics, and Disruptive Technologies. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 249-250.	0.6	0
10	Unapproved drugs â€“ A fix to an unintended consequence of an FDA policy. <i>Ocular Surface</i> , 2021, 21, 351-354.	2.2	2
11	N-of-1 Clinical Trials: A Scientific Approach to Personalized Medicine for Patients with Rare Retinal Diseases Such as Retinitis Pigmentosa. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 495-501.	0.6	2
12	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 383-385.	0.6	0
13	Compounded medications for ocular surface disease. <i>Ocular Surface</i> , 2021, 22, 267-270.	2.2	2
14	Keeping up with current science --- how much is enough?. <i>Ocular Surface</i> , 2020, 18, 186-189.	2.2	2
15	Regulatory and Developmental Aspects of Biomarkers in the Treatment of Ocular Surface Disease. <i>Eye and Contact Lens</i> , 2020, 46, S106-S108.	0.8	1
16	Five variables that rule your life â€“ Home mortgage and biostatistical power. <i>Ocular Surface</i> , 2020, 18, 533-536.	2.2	5
17	FDA review times for new drugs in ophthalmology. <i>Ocular Surface</i> , 2020, 18, 963-966.	2.2	4
18	Ocular Drug Delivery Systems Using Contact Lenses. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 595-601.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 267-268.	0.6	0
20	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 199-200.	0.6	0
21	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 73-74.	0.6	0
22	Peri-Operative Intracameral Antibiotics: The Perfect Storm?. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 668-671.	0.6	6
23	Treating ocular surface disease – A daily experience. Ocular Surface, 2020, 18, 345-348.	2.2	0
24	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 135-136.	0.6	0
25	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 319-321.	0.6	0
26	Retinal Detachment: Patient Perspective and Electronic Health Records. American Journal of Ophthalmology, 2019, 208, 64-67.	1.7	3
27	Collaboration or competition: Take your pick. Ocular Surface, 2019, 17, 833-837.	2.2	0
28	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 421-422.	0.6	0
29	Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Expert Review of Ophthalmology, 2019, 14, 191-197.	0.3	2
30	Treatment Duration and Side Effect Profile of Long-term Use of Intravitreal Preservative-free Triamcinolone Acetonide in Uveitis. American Journal of Ophthalmology, 2019, 202, 151.	1.7	0
31	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 77-78.	0.6	0
32	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 1-2.	0.6	2
33	Real world evidence for pharmaceuticals. Ocular Surface, 2019, 17, 584-588.	2.2	8
34	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 263-264.	0.6	0
35	Re: Rosenfeld etÂal.: Lessons from recent phase III trial failures: don't design phase III trials based on retrospective subgroup analyses from phase II trials (Ophthalmology. 2018;125:1488-1491). Ophthalmology, 2019, 126, e31-e32.	2.5	0
36	Calculus and tear flow. Ocular Surface, 2019, 17, 365-368.	2.2	0

#	ARTICLE	IF	CITATIONS
37	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 201-202.	0.6	0
38	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 137-137.	0.6	0
39	Regulatory Requirements for Cell-Based Therapy for Degenerative Retinal Disease. Pancreatic Islet Biology, 2019, , 97-107.	0.1	0
40	Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). American Journal of Ophthalmology, 2019, 200, 130-137.	1.7	78
41	How many vs. how much. Ocular Surface, 2019, 17, 167-171.	2.2	3
42	Compared to what? The placebo effect in dry eye therapy. Ocular Surface, 2018, 16, 265-269.	2.2	4
43	The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 380-386.	0.6	87
44	Slit Lamp-Based Ocular Scoring Systems: Commentary. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 237-238.	0.6	1
45	Eyes on New Product Development: Preclinical Research. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 311-311.	0.6	0
46	Eyes on New Product Development: Preclinical Research. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 4-6.	0.6	0
47	Thoughts on improving medication use. Ocular Surface, 2018, 16, 191-195.	2.2	1
48	A Drug to Prevent Pediatric Myopia—What Would it Take?. Eye and Contact Lens, 2018, 44, 220-223.	0.8	4
49	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 233-234.	0.6	0
50	Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase-Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and 2). Ocular Surface, 2018, 16, 191-195.	0.6	0
51	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 555-556.	0.6	0
52	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 657-658.	0.6	0
53	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 603-604.	0.6	0
54	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 487-488.	0.6	0

#	ARTICLE	IF	CITATIONS
55	How a drug developer thinks about a new ophthalmic product. <i>Ocular Surface</i> , 2018, 16, 390-392.	2.2	1
56	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 373-373.	0.6	0
57	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 427-428.	0.6	0
58	Re: "Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes" by Sekine et al. (<i>J. Ocul. Pharmacol. Ther.</i> 2018;34:280-286). <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 429-430.	0.6	0
59	Recent milestone U.S. ophthalmic product approvals and clearances. <i>Ocular Surface</i> , 2018, 16, 487-491.	2.2	1
60	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 1-2.	0.6	0
61	Generally Regarded As Safe. <i>Ocular Surface</i> , 2017, 15, 152-155.	2.2	3
62	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 129-131.	0.6	0
63	Chemistry matters!. <i>Ocular Surface</i> , 2017, 15, 264-267.	2.2	5
64	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 214-215.	0.6	0
65	New classes of glaucoma medications. <i>Current Opinion in Ophthalmology</i> , 2017, 28, 161-168.	1.3	28
66	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 65-65.	0.6	1
67	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 705-706.	0.6	0
68	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 573-573.	0.6	0
69	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 645-646.	0.6	0
70	Anti-science in the 21st century. <i>Ocular Surface</i> , 2017, 15, 813-819.	2.2	0
71	TFOS DEWS II Introduction. <i>Ocular Surface</i> , 2017, 15, 269-275.	2.2	180
72	TFOS DEWS II Clinical Trial Design Report. <i>Ocular Surface</i> , 2017, 15, 629-649.	2.2	73

#	ARTICLE	IF	CITATIONS
73	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 499-500.	0.6	0
74	TFOS DEWS II Report Executive Summary. Ocular Surface, 2017, 15, 802-812.	2.2	502
75	New pharmacotherapy for the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1939-1946.	0.9	17
76	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 423-425.	0.6	0
77	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 335-336.	0.6	0
78	Cannabinoids for treatment of glaucoma. Current Opinion in Ophthalmology, 2016, 27, 146-150.	1.3	55
79	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 185-185.	0.6	0
80	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 1-2.	0.6	1
81	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 133-134.	0.6	0
82	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 238-239.	0.6	0
83	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 483-483.	0.6	0
84	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 563-564.	0.6	0
85	What Determines How Much Your Patient Pays for Their Medication in the United States?. American Journal of Ophthalmology, 2016, 167, 48-51.	1.7	8
86	Unapproved Ophthalmic Drugs. Ocular Surface, 2016, 14, 317-320.	2.2	1
87	Natural Does Not Mean Safe. Ocular Surface, 2016, 14, 515-519.	2.2	1
88	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 341-342.	0.6	0
89	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 639-639.	0.6	0
90	Time to Take Your Medicines, Seriously. Ocular Surface, 2016, 14, 410-415.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 401-402.	0.6	1
92	Product Exclusivity Granted by the U.S. Food and Drug Administration. Ocular Surface, 2016, 14, 74-76.	2.2	4
93	How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 5-10.	0.6	13
94	Ocular pharmacology. Journal of Clinical Pharmacology, 2016, 56, 517-527.	1.0	34
95	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 65-66.	0.6	0
96	Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. British Journal of Ophthalmology, 2016, 100, 339-344.	2.1	81
97	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 587-588.	0.6	0
98	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 311-313.	0.6	0
99	The Right to Try. Ocular Surface, 2015, 13, 88-91.	2.2	13
100	Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure. Ophthalmology, 2015, 122, 302-307.	2.5	120
101	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 61-62.	0.6	0
102	The Importance of A Priori Statistical Planning in Controlled Clinical Trials. American Journal of Ophthalmology, 2015, 160, 4-5.e1.	1.7	7
103	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 187-188.	0.6	0
104	The "€"in JOPT. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 129-129.	0.6	4
105	Ocular Hypotensive Safety and Systemic Absorption of AR-13324 Ophthalmic Solution in Normal Volunteers. American Journal of Ophthalmology, 2015, 159, 980-985.e1.	1.7	38
106	Investing in New Therapies for Ocular Surface Disease. Ocular Surface, 2015, 13, 263-267.	2.2	2
107	Can I Use Those Eyedrops after the Expiration Date?. Ocular Surface, 2015, 13, 169-173.	2.2	5
108	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 130-130.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 363-364.	0.6	0
110	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 257-257.	0.6	0
111	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 1-1.	0.6	0
112	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 509-510.	0.6	0
113	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 445-446.	0.6	2
114	Do Genes Matter in Treating Eye Disease?. Ocular Surface, 2015, 13, 346-349.	2.2	2
115	Ocular Hypotensive Medications. , 2015, , 521-524.		2
116	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 603-604.	0.6	0
117	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 525-526.	0.6	0
118	Eyes on New Product Development: Trabecular Meshwork. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 83-84.	0.6	2
119	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 371-372.	0.6	0
120	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 301-302.	0.6	0
121	Phases of Clinical Development. Ocular Surface, 2014, 12, 307-311.	2.2	0
122	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 799-799.	0.6	0
123	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 445-446.	0.6	0
124	Some Are More Equal Than Others. Ocular Surface, 2014, 12, 155-158.	2.2	4
125	Why Aren't There More Pharmacotherapies for Dry Eye?. Ocular Surface, 2014, 12, 227-230.	2.2	13
126	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 2-3.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 687-687.	0.6	0
128	Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Delivery and Translational Research, 2014, 4, 303-309.	3.0	58
129	Confusion in Product Packaging. Ocular Surface, 2014, 12, 77-81.	2.2	1
130	Eyes on New Product Development: Ophthalmic Drug Delivery. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 90-91.	0.6	2
131	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 1-2.	0.6	0
132	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 449-449.	0.6	0
133	Fill Size for Ophthalmic Products. Ocular Surface, 2013, 11, 285-287.	2.2	1
134	What Does the Food and Drug Administration Safety and Innovation Act Mean For You?. Ocular Surface, 2013, 11, 206-209.	2.2	6
135	Where do Unused Medications go When They Die?. Ocular Surface, 2013, 11, 139-142.	2.2	4
136	Quality of Generic Ophthalmic Drugs. Ocular Surface, 2013, 11, 54-57.	2.2	6
137	New Pharmacological Treatments for Dry Eye Disease. Current Ophthalmology Reports, 2013, 1, 75-79.	0.5	0
138	Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. British Journal of Ophthalmology, 2013, 97, 567-572.	2.1	22
139	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 513-514.	0.6	0
140	Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 674-680.	0.6	26
141	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 611-611.	0.6	0
142	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 701-701.	0.6	0
143	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 785-785.	0.6	0
144	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 379-379.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 843-843.	0.6	0
146	Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy?. Translational Vision Science and Technology, 2013, 2, 1.	1.1	15
147	Rho kinase inhibitors for the treatment of glaucoma. Drugs of the Future, 2013, 38, 107.	0.0	13
148	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 557-558.	0.6	0
149	Drug Shortages. Ocular Surface, 2012, 10, 51-54.	2.2	1
150	How Do Drugs Get Their Brand Names?. Ocular Surface, 2012, 10, 117-120.	2.2	1
151	How Should We Display Our Data? What Is the Best Number?. Ocular Surface, 2012, 10, 193-198.	2.2	1
152	The Benefit/Risk of Good Therapeutics. Ocular Surface, 2012, 10, 264-266.	2.2	1
153	Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension. American Journal of Ophthalmology, 2011, 152, 834-841.e1.	1.7	123
154	The Development of Drugs vs Devices. Ocular Surface, 2011, 9, 56-58.	2.2	4
155	Withdrawal of Approved Drugs. Ocular Surface, 2011, 9, 111-114.	2.2	3
156	Drop Size: An Issue Wrapped in a Non-Issue Wrapped in an Issue. Ocular Surface, 2011, 9, 185-188.	2.2	1
157	Stephen Jay Gould and Statistics, 2011 Version. Ocular Surface, 2011, 9, 239-241.	2.2	1
158	Treatment Adherence in Ophthalmology and Astrophysics. Ocular Surface, 2010, 8, 91-95.	2.2	5
159	Data Monitoring Committees. Ocular Surface, 2010, 8, 40-43.	2.2	6
160	Personalized Medicine and the Ocular Surface. Ocular Surface, 2010, 8, 157-160.	2.2	3
161	The Accelerated Drug Approval. Ocular Surface, 2010, 8, 205-207.	2.2	12
162	Intraocular Pressure and Visual Field Damage as Risk Factors for Visual Field Progression in Filtering Surgery. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 452-458.	0.4	0

#	ARTICLE	IF	CITATIONS
163	An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma. <i>JAMA Ophthalmology</i> , 2009, 127, 732.	2.6	186
164	Ophthalmic Drug Delivery: Development and Regulatory Considerations. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 539-543.	2.3	76
165	Authorship Policy. <i>American Journal of Ophthalmology</i> , 2009, 147, 184.	1.7	0
166	Clinical Trial Registry Update. <i>Ocular Surface</i> , 2009, 7, 212-214.	2.2	4
167	The "In-between" New Drug Application. <i>Ocular Surface</i> , 2009, 7, 53-55.	2.2	12
168	Just a Small, Proof-of-Concept Study. <i>Ocular Surface</i> , 2009, 7, 111-114.	2.2	3
169	Regression to the Mean. <i>Ocular Surface</i> , 2009, 7, 163-165.	2.2	9
170	Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. <i>Journal of AAPOS</i> , 2008, 12, 332-339.	0.2	145
171	Orphan Drugs. <i>Ocular Surface</i> , 2008, 6, 52-55.	2.2	3
172	Clinical Indications for Ophthalmic Corticosteroids. <i>Ocular Surface</i> , 2008, 6, 199-202.	2.2	5
173	Conducting Clinical Trials: Even More Challenges. <i>Ocular Surface</i> , 2008, 6, 99-101.	2.2	3
174	What is a New Drug?. <i>Ocular Surface</i> , 2008, 6, 143-146.	2.2	5
175	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 61-78.	4.2	34
176	Timolol Concentrations in Breast Milk of a Woman Treated for Glaucoma: Calculation of Neonatal Exposure. <i>Journal of Glaucoma</i> , 2008, 17, 510.	0.8	1
177	The Role of Pharmaceutical Companies in Sponsored Research. <i>Ophthalmology</i> , 2007, 114, 1037-1038.	2.5	18
178	Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use. <i>American Journal of Ophthalmology</i> , 2007, 144, 533-540.e2.	1.7	291
179	Pharmacotherapy: How Much Drug Is There?. <i>Ocular Surface</i> , 2007, 5, 58-61.	2.2	1
180	Clinical Trial Registration. <i>Ocular Surface</i> , 2007, 5, 316-317.	2.2	0

#	ARTICLE	IF	CITATIONS
181	Notification vs Approval. Ocular Surface, 2007, 5, 255-258.	2.2	0
182	A Double-Masked, Randomized, Parallel Comparison of a Fixed Combination of Bimatoprost 0.03%/Timolol 0.5% with Non-Fixed Combination use in Patients with Glaucoma or Ocular Hypertension. European Journal of Ophthalmology, 2007, 17, 53-62.	0.7	80
183	Research Ethics. Ocular Surface, 2006, 4, 103-106.	2.2	1
184	Adaptive Trials. Ocular Surface, 2006, 4, 215-217.	2.2	0
185	Risks and Benefits. Ocular Surface, 2006, 4, 58-60.	2.2	15
186	Glaucoma and Intravitreal Steroids. Ophthalmology, 2006, 113, 1688-1688.	2.5	0
187	Mechanics of the Food and Drug Administration's Form 1571: Investigational New Drug Application. Retina, 2005, 25, S96-S97.	1.0	4
188	Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers. Current Medical Research and Opinion, 2005, 21, 369-373.	0.9	4
189	What Does It Mean When a Company Says That a Product Is "Approvable"? Ocular Surface, 2005, 3, 63-64.	2.2	1
190	Should You Be a Clinical Investigator for a New Pharmaceutical?. Ocular Surface, 2005, 3, 168-170.	2.2	1
191	Is the World Flat for Pharmaceuticals?. Ocular Surface, 2005, 3, 212-214.	2.2	0
192	Systemic Medications and Glaucoma Patients Presented at: American Glaucoma Society meeting, March, 2005; Snowbird, Utah. Study sponsored by Alcon Laboratories, Inc., Fort Worth, Texas. Drs Robin and Novack are consultants to and Mr Covert is an employee of and stockholder in Alcon Laboratories, Inc. Dr Robin is also a consultant to Pfizer and Merck.. Ophthalmology, 2005, 112, 1849.e1-1849.e2.	2.5	15
193	Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisert [®] Intravitreal Implantation in Rabbits Over a 1-Year Period. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 269-275.	0.6	94
194	The CONSORT Statement for Publication of Controlled Clinical Trials. Ocular Surface, 2004, 2, 45-46.	2.2	7
195	Thoughts Generated by the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. Ocular Surface, 2004, 2, 212-214.	2.2	11
196	What Happens to Patients at the End of the Clinical Trial?. Ocular Surface, 2004, 2, 267-269.	2.2	0
197	Development of Topical Agents. Ocular Surface, 2004, 2, 166-168.	2.2	0
198	A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension*1. Clinical Therapeutics, 2004, 26, 541-551.	1.1	32

#	ARTICLE	IF	CITATIONS
199	Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children With Myopia. JAMA Ophthalmology, 2004, 122, 1667.	2.6	112
200	Pupillary response to four concentrations of pilocarpine in normal subjects. American Journal of Ophthalmology, 2003, 135, 259-260.	1.7	0
201	Decoding the Package Insert: Adverse Events. Ocular Surface, 2003, 1, 202-203.	2.2	1
202	Compliance Issues in Manufacturing of Drugs. Ocular Surface, 2003, 1, 80-85.	2.2	99
203	How Are Tear Lubricant Products Regulated in the US?. Ocular Surface, 2003, 1, 86.	2.2	3
204	Decoding the Packaging Insert: Indications. Ocular Surface, 2003, 1, 150-151.	2.2	7
205	Transconjunctival mitomycin-C in needle revisions of failing filtering blebs. Ophthalmology, 2003, 110, 734-742.	2.5	63
206	Fluorometholone in children. Ophthalmology, 2003, 110, 1072-1073.	2.5	0
207	Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma ¹¹ The authors have no proprietary interest in any of the equipment or materials mentioned in this article.. Ophthalmology, 2003, 110, 895-899.	2.5	45
208	Emerging drugs for ophthalmic diseases. Expert Opinion on Emerging Drugs, 2003, 8, 251-266.	1.0	7
209	Pharmacologic Treatments for Dry Eye. Cornea, 2002, 21, 4-5.	0.9	7
210	Dear Dr. Walson. Clinical Therapeutics, 2002, 24, 1477-1478.	1.1	2
211	New Glaucoma Medications in the Geriatric Population: Efficacy and Safety. Journal of the American Geriatrics Society, 2002, 50, 956-962.	1.3	55
212	Drug Development Issues in Pharmacological Treatments for Dry Eye. Advances in Experimental Medicine and Biology, 2002, 506, 1117-1120.	0.8	0
213	Commercially Available Ocular Hypotensive Products: Preservative Concentration, Stability, Storage, and In-life Utilization. Journal of Glaucoma, 2001, 10, 483-486.	0.8	28
214	Ocular Safety of INS365 Ophthalmic Solution: A P2Y2 Agonist In Healthy Subjects. Journal of Ocular Pharmacology and Therapeutics, 2001, 17, 173-179.	0.6	33
215	Financing New Drug Development in Ophthalmology. Journal of Glaucoma, 2000, 9, 195-199.	0.8	4
216	Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration. American Journal of Ophthalmology, 2000, 130, 664-665.	1.7	3

#	ARTICLE	IF	CITATIONS
217	A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. None of the investigators had a proprietary interest in loteprednol etabonate. Ophthalmology, 1999, 106, 362-369.	2.5	53
218	Comparative Irritancy Study among Retinoid Creams and Gels. Journal of Cutaneous Medicine and Surgery, 1999, 3, 298-301.	0.6	11
219	A Single-Blind, Crossover Comparison of the Pharmacokinetics and Cognitive Effects of a New Diazepam Rectal Gel with Intravenous Diazepam. Epilepsia, 1998, 39, 520-526.	2.6	78
220	Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. Journal of Cataract and Refractive Surgery, 1998, 24, 1480-1489.	0.7	58
221	Failure to Detect Systemic Levels, and Effects of Loteprednol Etabonate and its Metabolite, PJ-91, Following Chronic Ocular Administration. Journal of Ocular Pharmacology and Therapeutics, 1998, 14, 153-158.	0.6	29
222	Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration. American Journal of Ophthalmology, 1998, 126, 122-126.	1.7	8
223	A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology, 1998, 102, 251-255.	1.5	67
224	Change in Intraocular Pressure During Long-Term Use of Loteprednol Etabonate. Journal of Glaucoma, 1998, 7, 266-269.	0.8	42
225	Ophthalmic Drug Development. Journal of Glaucoma, 1998, 7, 202-209.	0.8	2
226	Ocular toxicology. Current Opinion in Ophthalmology, 1997, 8, 88-92.	1.3	9
227	The Role of Mitomycin Treatment Duration and Previous Intraocular Surgery on the Success of Trabeculectomy Surgery. Journal of Glaucoma, 1997, 6, 3-9.	0.8	19
228	A Placebo-controlled, Double-masked Evaluation of Mitomycin C in Combined Glaucoma and Cataract Procedures. Ophthalmology, 1996, 103, 1934-1942.	2.5	92
229	Excessive β_2 -Blockade With Timolol Eye Drops. JAMA - Journal of the American Medical Association, 1996, 275, 985.	3.8	4
230	Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?. JAMA Ophthalmology, 1994, 112, 726.	2.6	0
231	Industrial publication of controlled clinical trial data. Clinical Pharmacology and Therapeutics, 1993, 53, 495-496.	2.3	2
232	Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. Journal of Cataract and Refractive Surgery, 1993, 19, 481-487.	0.7	19
233	Vitreous Surgery for Macular Holes. Ophthalmology, 1993, 100, 1671-1676.	2.5	353
234	New Medical Treatments for Glaucoma. International Ophthalmology Clinics, 1993, 33, 183-202.	0.3	12

#	ARTICLE	IF	CITATIONS
235	The Development of New Drugs for Ophthalmology. American Journal of Ophthalmology, 1992, 114, 357-364.	1.7	2
236	Once-daily versus Twice-daily Levobunolol (0.5%) Therapy. Ophthalmology, 1992, 99, 424-429.	2.5	26
237	Memory-enhancing effects of post-training dipivefrin and epinephrine: Involvement of peripheral and central adrenergic receptors. Brain Research, 1992, 572, 81-86.	1.1	109
238	A Comparison of the Ocular Hypotensive Efficacy of Once-daily and Twice-daily Levobunolol Treatment. Ophthalmology, 1989, 96, 8-11.	2.5	26
239	Trabecular outflow facility determined by fluorophotometry in human subjects. Experimental Eye Research, 1989, 48, 621-625.	1.2	54
240	The Blood-Aqueous and Blood-Brain Barriers to Permeability. American Journal of Ophthalmology, 1988, 105, 412-416.	1.7	18
241	Ocular Hypotensive Efficacy of 0.25% Levobunolol Instilled Once Daily. Ophthalmology, 1988, 95, 252-255.	2.5	17
242	Levobunolol and Betaxolol. Ophthalmology, 1988, 95, 735-741.	2.5	36
243	The Effect of Twice Daily Nadolol on Intraocular Pressure. American Journal of Ophthalmology, 1988, 105, 435-436.	1.7	1
244	Prophylactic Treatment of intraocular Pressure Elevations after Neodymium:YAG Laser Posterior Capsulotomies and Extracapsular Cataract Extractions with Levobunolol. Ophthalmology, 1988, 95, 713-718.	2.5	32
245	Levobunolol compared with timolol: a four-year study.. British Journal of Ophthalmology, 1988, 72, 892-896.	2.1	20
246	Long-term Evaluation of 0.25% Levobunolol and Timolol for Therapy for Elevated Intraocular Pressure. JAMA Ophthalmology, 1988, 106, 614-618.	2.6	25
247	Effect of Changing Medication Regimens in Glaucoma Patients. Ophthalmologica, 1988, 196, 23-28.	1.0	25
248	Effect of changing beta-blocker treatment in six patients allergic to timolol. Cutaneous and Ocular Toxicology, 1987, 6, 179-181.	0.3	1
249	Ophthalmic beta-blockers since timolol. Survey of Ophthalmology, 1987, 31, 307-327.	1.7	107
250	The effect of levobunolol on aqueous humor dynamics. Experimental Eye Research, 1987, 44, 49-54.	1.2	36
251	Glaucoma Treatment With Once-Daily Levobunolol. American Journal of Ophthalmology, 1987, 104, 443-444.	1.7	8
252	Aqueous Humor, Cerebrospinal Fluid, and Atriopeptin. American Journal of Ophthalmology, 1987, 104, 297-300.	1.7	7

#	ARTICLE	IF	CITATIONS
253	Plasma Levobunolol Levels following Topical Administration with Reference to Systemic Side Effects. <i>Ophthalmologica</i> , 1987, 194, 194-200.	1.0	15
254	Epinephrine-induced memory facilitation: attenuation by adrenoceptor antagonists. <i>European Journal of Pharmacology</i> , 1986, 129, 189-193.	1.7	43
255	Glaucoma Treatment with Once-Daily Levobunolol: Reply. <i>American Journal of Ophthalmology</i> , 1986, 102, 546-547.	1.7	0
256	Glaucoma Treatment With Once-Daily Levobunolol. <i>American Journal of Ophthalmology</i> , 1986, 101, 298-304.	1.7	62
257	Levobunolol for the long-term treatment of glaucoma. <i>General Pharmacology</i> , 1986, 17, 373-377.	0.7	12
258	Levobunolol. <i>JAMA Ophthalmology</i> , 1985, 103, 375.	2.6	30
259	Long-term ocular hypotensive effect of levobunolol: results of a one-year study.. <i>British Journal of Ophthalmology</i> , 1985, 69, 593-599.	2.1	24
260	Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure. <i>JAMA Ophthalmology</i> , 1985, 103, 379-382.	2.6	45
261	Levobunolol. <i>Ophthalmology</i> , 1985, 92, 1271-1276.	2.5	49
262	Minimum Concentration of Levobunolol Required To Control Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 1985, 99, 18-22.	1.7	19
263	Levobunolol vs Timolol for Open-Angle Glaucoma and Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 1985, 99, 11-17.	1.7	44
264	On Cardiovascular Effects of Topical Glaucoma Therapy [2(2&3):99, 1983]. <i>Cutaneous and Ocular Toxicology</i> , 1984, 3, 243-246.	0.3	3
265	Flurazepam and triazolam: Dose-response and time-response evaluation on cat sleep. <i>Electroencephalography and Clinical Neurophysiology</i> , 1984, 57, 277-288.	0.3	1
266	The clinical trial outline. <i>Contemporary Clinical Trials</i> , 1984, 5, 311.	2.0	0
267	Predictive value of muscle relaxant models in rats and cats. <i>Journal of Pharmacological Methods</i> , 1983, 10, 175-183.	0.7	17
268	Studies on the efficacy and depressant potential of muscle relaxants in mice. <i>Drug Development Research</i> , 1982, 2, 383-386.	1.4	16
269	Malfunctioning Halothane Vaporizer. <i>Anesthesia and Analgesia</i> , 1981, 60, 121.	1.1	4
270	Development of responses of globus pallidus and entopeduncular nucleus neurons to stimulation of the caudate nucleus and precruciate cortex. <i>Experimental Neurology</i> , 1979, 66, 479-492.	2.0	19

#	ARTICLE	IF	CITATIONS
271	Caudate neuronal responses evoked by cortical stimulation: contribution of an indirect corticothalamic pathway. <i>Brain Research</i> , 1979, 173, 331-336.	1.1	10
272	Anticonvulsant effects of benzhydryl piperazines on pentylenetetrazol-induced seizures in mice. <i>Neuropharmacology</i> , 1978, 17, 659-663.	2.0	6
273	Fentanyl: Cumulative effects and development of short-term tolerance. <i>Neuropharmacology</i> , 1978, 17, 77-82.	2.0	9
274	Eyes on New Product Development: Long-Acting Ocular Drug Delivery Technologies Addressing Unmet Needs in Ophthalmology. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 0, , .	0.6	0